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Abstract
The incidence of extrahepatic cholangiocarcinoma is increasing worldwide and is often in an advanced stage at diagnosis
and difficult to treat. The TNM (tumor node metastasis) cancer staging system predicts survival on the basis of tumor
histopathology and the presence of distant metastases. However, numerous prognostic factors have been described that are
not included in the TNM system. This review focuses on the prognostic significance of clinical, surgical, and
histopathological factors as reported in the literature. Overall, the most important independent prognostic factors for
long-term survival are negative surgical margins, lymph node status, and differentiation grade of the tumor. Further
improvement of staging systems and identification of prognostic factors are crucial if we are to better select patients for
surgical and adjuvant therapy and, hence, increase the rate of curative resections.
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Introduction
Cholangiocarcinoma (CCA) can be classified into
intrahepatic and extrahepatic CCA, the latter includ-
ing distal and hilar cholangiocarcinoma (HCCA),
depending on its location within the biliary tree [1].
Surgical treatment, consisting of hilar resection with
extended hepatectomy, pancreatoduodenectomy
(PD), or sometimes local bile duct resection, is the
only curative treatment option [26]. Despite com-
prehensive preoperative staging to select patients for
potentially curative resection, many patients present
with recurrences within 2 years after tumor resection.
Overall, 5-year survival rates of 20% to 35% have
been reported after resection [615].
There is no single staging system for all CCA,
reflecting the different patho-biology of intrahepatic
and extrahepatic tumors [16]. For staging of intrahe-
patic CCA, the proposed TNM (tumor node metas-
tasis) system has been shown to correlate with survival
after hepatic resection [17]. To stage extrahepatic
CCA, accounting for approximately two-thirds of all
CCA, a different pTNM system is used [18,19].
Several modifications and alternatives have been im-
plemented with the objective of improving the prog-
nostic and therapeutic predictions for each cancer
stage. However, to improve the currently available
staging systems, additional clinical and histopatholo-
gic factors have been suggested [20].
The current study reviews the major clinical-patho-
logical factors, operative techniques, and adjuvant
treatment strategies that influence survival of resect-
able extrahepatic CCA. Future directions towards
improving staging systems are proposed.
Methods
A review of the English-language literature (January
1995 through September 2007) concerning resectable
CCA was performed (intrahepatic, gallbladder, and
periampullary adenocarcinoma were excluded) focus-
ing on the prognostic power of clinical, surgical, and
histopathological factors in relation to resectable
extrahepatic CCA.
Results
Clinical prognostic factors (summarized in Table I)
Age and sex. In case of comparable therapy, age was
found not to be of any prognostic significance in
several studies [8,21,22]. However, two studies
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showed a worse long-term outcome for older patients
[9,12]. Three studies reported a survival benefit in
multivariate analyses for female compared to male
patients with extrahepatic CCA [8,9,23].
Symptoms at initial presentation. The majority of
patients with extrahepatic CCA present with jaundice.
Three studies describe a long-term favorable prog-
nostic effect of low initial plasma bilirubin level in
univariate analysis [24,25] as well as in multivariate
analysis [2]. Weight loss is usually a reflection of
advanced disease. However, none of the studies found
this clinical sign to be a prognostic factor.
Co-morbidity. It has been suggested that the presence
of hepatolithiasis hinders diagnosis of underlying
CCA preoperatively and precipitates biliary sepsis,
which affects resectability. Hepatolithiasis per se,
however, did not influence long-term survival [26].
Tumor location. Extrahepatic CCAs are subclassified
mostly according to their location within the biliary
tree. It has been suggested that CCAs in the distal or
middle part have better prognosis because these give
rise to total obstruction and therefore are detected
earlier, whereas proximal tumors tend to commence
with partial biliary obstruction consequently resulting
in fewer complaints and late jaundice. However, in
one study there was only a survival benefit for patients
with distal lesions at univariate analysis [27], and in
the other two studies no difference in survival was
found in respect of tumor location [11,28].
BismuthCorlette staging system. Hilar lesions can
be classified according to location and segmental
infiltration into the biliary tree, as suggested by the
BismuthCorlette system [29]. In several studies, this
staging system had no predictive value for survival
[7,21,22,3033]. In two studies at univariate analysis
[34,35] and in another at multivariate analysis [25] a
favorable outcome for stages I and II was observed.
Chemoradiation therapy. The main goal of adjuvant
chemoradion therapy is improvement of local control
and consequently survival. In a retrospective analysis,
improved survival was observed for patients with
adjuvant radiation therapy [36]; however, this was
not confirmed in other studies [37,38]. In one study,
patients referred after neoadjuvant chemotherapy had
an unexpected survival benefit [9]. Furthermore, a
significant improvement in survival was demonstrated
after adjuvant chemotherapy in both univariate ana-
lysis [39,40] and multivariate analysis [10,41].
Surgical prognostic factors (summarized in Table I)
Type of operation. HCCA requires resection of the
hepatic duct confluence, usually with extended liver
resection. Distal and middle CCAs do not involve the
hepatic duct confluence. In such cases, PD or
occasionally local bile duct resection can be per-
formed to attain cure. As mentioned above, no studies
have shown a prognostic difference of distal and
proximal tumors. The extent of surgical resection in
proximal (hilar) tumors, however, has been crucial in
the past two decades.
Caudate lobe resection. Because of frequent anterior
and posterior infiltration of the tumor in the hepatic
hilum, liver resection is advocated in combination
with resection of segment 4 (Sg 4) and complete
excision of the caudate lobe (Sg 1). Japanese sur-
geons, in particular, demonstrated survival benefit of
a more aggressive approach [4244]. In one series,
multivariate analysis was performed in patients who
had had an R0 resection to determine whether
additional significant variables might emerge. This
analysis identified concomitant liver resection as the
only predictor of survival after resection with negative
margins [3].
Table I. Clinical and surgical prognostic factors in extrahepatic CCA.
Clinical/surgical factor Prognostic impact Favouring survival benefit References
Age Minor Younger age [9,12]
Sex Considerable Female [8,9,23]
Level of jaundice Considerable Low initial plasma bilirubin level [2,24,25]
Hepatolithiasis None
Tumor location Dubious Distal lesion [27]
BismuthCorlette staging Dubious Type I, II lesion [25,34,35]
Chemoradiation therapy Considerable (Neo)adjuvant therapy [9,10,3941]
Type of operation Considerable Concomitant PHx [3,67]
Portal vein resection Considerable Portal vein resected [3,7,14,32,45]
Surgical complications Considerable No blood transfusion [23,33]
Prognostic impact on clinical and surgical factors is scored as none (no evidence), dubious (conflicting evidence), minor (evidence from
univariate analysis), considerable (evidence from uni- and multivariate analysis) and strong (evidence from several multivariate analyses).
PHxPartial hepatectomy.
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Portal vein resection. Portal vein invasion was pre-
viously considered a main cause of unresectability of
HCCA. However, this view has been abandoned. Two
studies found a survival benefit of portal vein resec-
tion in univariate analysis [3,32], and one in multi-
variate analysis [14]. In a multivariate analysis after
R0 resection, additional resection of the portal vein
was the only variable with a significant influence on
patient survival [7,45]. However, microscopic inva-
sion of the resected portal vein was found in only 12%
of patients [7]. In another study, the microscopic
invasion rate of the resected portal veins was 69% [6].
These authors did not find a survival benefit of portal
vein resection.
Surgical complications. A prognostic relation between
the amount of intraoperative blood loss (and conse-
quently blood transfusions) and overall survival has
been hypothesized. In patients resected for HCCA,
two studies confirmed this hypothesis in multivariate
analysis [23,33]. A study focusing on overall post-
operative complications found a negative survival
effect resulting from these complications, although
this effect was not identified as an independent factor
[9].
Pathologic prognostic factors (summarized in Table II)
Pathologic staging systems. The 6th edition of the
American Joint Committee on Cancer [19] (AJCC)
and Union Internationale Contre le Cancer [18]
(UICC) for adenocarcinoma of the extrahepatic
biliary tract are TNM based. Compared to the 5th
edition these systems now also focus on vascular
invasion requiring vascular resection and reconstruc-
tion, as well as lymph node (LN) metastasis [20].
Obviously, stage groupings should represent strong
independent prognostic factors, with a higher stage
implying more advanced disease. Surprisingly, only
five studies confirmed the TNM staging system as an
independent prognostic factor [2,35,4648]. In sev-
eral studies, the staging system had no predictive
value for survival [3,8,21,32,33,49] and, in a few, only
in univariate analysis [23,31,50].
Radicality. The incidence of a microscopically positive
surgical resection margin in patients who have under-
gone a resection with curative intent can increase to
50%. The most consistent independent determinant
for long-term survival after potentially curative resec-
tion of a biliary tumor is the surgical margin status
of the resected bile duct [3,79,14,25,3032,41,
4549,5157]. A study focusing particularly on radi-
cality found a survival benefit for patients with
residual carcinoma in situ in comparison to invasive
carcinoma at the ductal resection margins [52].
Tumor invasion. Increased depth of tumor invasion is
associated with the presence of lymphatic dissemina-
tion [13], vascular/perineural invasion, and is a known
independent prognostic parameter [47,58,59].
Lymph nodes. The incidence of LN involvement in
resected specimens has been reported to range from
30% to more than 50% [7,11,14,30,41,48,6062]. In
one study, already 55% of the T2 tumors had positive
LN [62]. The presence of lymphatic dissemination is
an important independent prognostic factor, as has
been confirmed in many studies [6,8,10,12,14,21,25,
3032,39,48,50,51,53,54,58,63].
Number of positive nodes (ratio). The chance of
identifying involved LNs increases with the number
of resected (pathologically identified) LNs and is
influenced by the extent of dissection. A higher
number of positive nodes indicates further progres-
sion of disease. Only two studies have reported a
worse survival in patients with a higher number of
positive LN metastases [41,58].
Table II. Pathological prognostic factors in extrahepatic CCA.
Pathologic factor Prognostic impact Favouring survival benefit References
TNM staging systems Considerable Early stage [2,35,4648]
Radicality Strong R0 resection [3,79,14,25,3032,41,4549,5157]
Tumor invasion Considerable Early stage [47,58,59]
LN metastases Strong Metastases absent (N0) [6,8,10,12,14,21,25,3032,39,48,50,51,53,54,58,63]
No. of positive LN Minor Fewer positive nodes [41,58]
Location of positive LN None
Micrometastases in LN Dubious Micrometastases absent [65]
Extracapsular LN involvement None
Differentiation grade Strong Good differentiation [2,3,68,25,28,35,45,49,50,52,56]
Vascular invasion Considerable No invasion [12,49]
Perineural invasion Considerable No invasion [7,45,66]
Prognostic impact on clinical and surgical factors is scored as none (no evidence), dubious (conflicting evidence), minor (evidence from
univariate analysis), considerable (evidence from uni- and multivariate analysis) and strong (evidence from several multivariate analyses).
LNLymph node.
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Location of positive LN. Although there is an individual
preference of lymphatic spread of adenocarcinomas in
the proximal, middle, and distal bile ducts [62], a
pericholedochal node in the hepatoduodenal ligament
is the most common site of metastasis [61]. Regional
and para-aortic LNs are frequently involved in ad-
vanced CCA and extended lymphadenectomy has
been suggested as providing a survival benefit in
selected patients [13]. Survival was favorable in the
presence of distant LN metastasis in selected patients
[13,20,64].
Micrometastases in LN. In one study, LN micrometas-
tases were detected in 24% of patients with pN0
disease, but this did not show any impact on survival
[49]. In another study, LN micrometastasis in CCA
had a negative effect on survival in univariate analysis
[65].
Extracapsular LN involvement. So far, no reports have
described the significance of extracapsular LN invol-
vement in extrahepatic CCA.
Differentiation grade. Microscopically, adenocarcino-
mas are graded as well differentiated, moderately
differentiated, or poorly differentiated. Lack of differ-
entiation increases the risk of lymphatic dissemination
and therefore has a negative effect on survival. The
grade of differentiation has been identified as an
independent prognosticator in several studies [2,3,
68,25,28,35,45,49,50,52,56].
Vascular invasion. The impact of blood vessel invasion
(microscopic venous invasion) has mainly been shown
in univariate analysis [6,46,51,58,59]. Two studies
reported vascular invasion as independent factor for
worse survival [12,49].
Perineural invasion. Perineural invasion refers to
growth of tumor along the nerve branches present
within the biliary tract tissue. This mechanism of
spread has shown prognostic significance in a few
studies in univariate analysis [6,21] as well as in
multivariate analysis [7,45,66].
Discussion
Overall, the most important independent prognostic
factors for long-term survival are negative surgical
margins, LN status, and differentiation grade of the
tumor. Therefore, all patients with a suspicious biliary
obstruction should be considered for laparotomy and
potential resection, as this provides the only chance
for cure. Despite an aggressive surgical approach and
advances in surgical techniques, the overall prognosis
of patients undergoing potentially curative resection
for extrahepatic CCA is still poor, with high local
failure rates and associated postoperative mortality.
The adequacy of the current pTNM staging system
has been questioned repeatedly, with several authors
proposing a revision of the system [3,6,16,20,58].
Firstly of note, the current systems (the Bismuth
Corlette and the AJCC/UICC) are not satisfactory,
because they fail to consider all of the relevant local,
tumor-related variables that determine respectability,
and they correlate poorly with survival. The Memorial
SloanKettering Cancer Center (MSKCC) devised a
staging system for HCCA that encompasses a full
radiological diagnosis and shows a correlation with
increasing T stage and survival [3,67]. Secondly, in
the current TNM staging system used for extrahepatic
CCA, only a N0 and a N1 classification exist. Several
studies propose including the number of positive LNs
[41,58]. Thirdly, one study focusing on the differ-
ences between the 5th and 6th TNM staging systems
concluded that cancer invasion of the portal bifurca-
tion and regional LN metastasis should be weighed
equally.
The World Health Organization classification of
extrahepatic CCA does not distinguish between distal
and HCCA. According to the current literature, the
prognostic significance of the location of an extra-
hepatic CCA is uncertain. Important independent
factors predicting survival were the same for distal and
proximal tumors. Therefore, there is a rationale for
classifying all patients with extrahepatic tumors in one
TNM staging system. However, the surgical proce-
dure to obtain the most consistent independent
prognosticator, i.e. a negative resection margin, is
completely different between distal and HCCA.
Several surgical prognostic factors were found to
have an impact on patient survival specifically in
patients with HCCA. One study showed a biological
difference between distal and hilar tumors [28]. These
findings favor a distinct staging system for distal and
proximal CCA.
Conclusions
The simplicity of the TNM system, covering all
extrahepatic CCA, is one of the reasons why it has
continued to be applied. However, because biological
diversity is high in patients with distal CCA or
HCCA, many authors feel that additional factors
can improve clinical staging. A challenge for the
future is therefore to develop a new, dynamic staging
system that includes the diverse variables which have
been shown to impact on prognosis. Further improve-
ment of staging systems and identification of prog-
nostic factors is therefore crucial as means towards
better selection of patients for appropriate surgical
and adjuvant therapy and, hence, towards increasing
the rate of curative resections.
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